Russell J. Cox served as Chief Executive Officer at Vital Therapies, Inc. from January 2018 to January 2019. Prior to joining Vital, Mr. Cox served as the Executive Vice President and Chief Operating Officer, of Jazz Pharmaceuticals plc, with responsibility for global commercial activities, R&D, manufacturing/technical operations, new product planning and global molecule leadership. Earlier, he served as Executive Vice President and Chief Commercial Officer in addition to other senior management roles at Jazz. Prior to Jazz, Mr. Cox served as Senior Vice President and Chief Commercial Officer of Ipsen Group, a pharmaceutical company headquartered in Paris, France, focused in oncology, neuroscience and rare diseases. He was also Vice President of Marketing at Tercica, Inc. prior to its acquisition by Ipsen Group and served as Vice President, Marketing with Scios Inc., which was acquired by Johnson & Johnson in 2003. Mr. Cox began his career at Genentech, Inc. where he was a Product Team Leader responsible for the growth hormone franchise and led numerous product launches as a Group Product Manager. Mr. Cox has served on the Board of Directors of Aeglea BioTherapeutics, Inc. since 2015. Mr. Cox received a B.S. degree in biomedical science from Texas A&M University.